Recently, a delegation led by Professor Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley, Professor Wang Jianxun, Chief Scientist, Dr. Fu Yuchen, Assistant to the Chairman, Ms.Sun Rui, Head of the Marketing Department, and Mr.Zhou Zhaobin, General Manager of its subsidiary Hong Kong Cell Valley, visited Pamela Youde Nethersole Eastern Hospital (hereinafter referred to as Hong Kong Eastern Hospital), the largest public hospital in the Eastern District of Hong Kong. Dr. So Kit Ying, Cluster Chief Executive of the Hong Kong Island East Cluster of the Hospital Authority, warmly welcomed the delegation alongside her core team and organized a symposium for in-depth discussions. Dr. Cheng Kam Chung, Chairman of the Greater China Cancer Foundation, a Justice of the Peace in Hong Kong, and a renowned philanthropist, also attended the meeting. Representatives from all parties engaged in extensive discussions regarding the advancement of clinical cell therapy projects.

Under the professional guidance of Dr. Chen Juan, Consultant in Clinical Oncology, and Dr. Xu Zishan, Consultant in Internal Medicine, the visiting team conducted an in-depth tour of key departments at Hong Kong Eastern Hospital, including Clinical Oncology and Hematology & Hematologic Oncology. Through this on-site visit, the team gained a comprehensive understanding of the hospital's overall operations, specialized facilities, and medical service processes. Hong Kong Eastern Hospital has 2,000 beds and over 6,000 staff members, providing public healthcare services in the eastern part of Hong Kong Island. Notably, the eastern district of Hong Kong Island is one of the most aging regions among the 18 districts of Hong Kong, with the population aged 60 and above accounting for nearly 30% of the total population, significantly higher than the citywide average of 21%. This makes the medical demand in the region particularly urgent.

At the symposium, Professor Shi Yuanyuan stated that Shenzhen Cell Valley is actively promoting its international strategic layout and has established a wholly-owned overseas subsidiary—Hong Kong Cell Valley. It has always been committed to maintaining close communication and cooperation with the Hospital Authority of Hong Kong and major medical institutions. Currently, Shenzhen Cell Valley has reached preliminary agreements on clinical applications and research collaborations with major hospitals within the network of Hong Kong Island East Hospital. It is also making full efforts to expedite the submission of procedures related to the import and export of cell products, thereby facilitating the smooth progress of cooperation projects between Shenzhen and Hong Kong.

Dr. So Kit Ying, Chief Executive of Hong Kong East Cluster, Hospital Authority, elaborated on the advantages of Pamela Youde Nethersole Eastern Hospital in clinical research and medical technology. She further pointed out that through recent in-depth exchanges during her multiple visits to the headquarters of Shenzhen Cell Valley and its partner medical institutions, and with the strong promotion of Shenzhen Cell Valley, Eastern Hospital has established preliminary cooperative relations with a number of Grade A Class 3 public hospitals in Shenzhen and jointly carried out a series of academic exchange activities.At the meeting, Dr. Cheng Kam Chung, Chairman of the Greater China Cancer Foundation, shared the foundation’s achievements in cancer prevention and treatment. He noted that the foundation fully supports medical cooperation between Shenzhen and Hong Kong, and is committed to providing high-quality medical services, affordable anti-cancer drugs and technologies for low-income cancer patients in Hong Kong.

As the symposium drew to a close, the participating delegates engaged in in-depth discussions on the details of future collaboration in the field of clinical treatment. All parties unanimously agreed that through joint efforts, the coordinated development of medical services between Shenzhen and Hong Kong could be further advanced, bringing more positive and significant health benefits to patients in both regions.